3 “Affordable Yet Compelling” Biotech Stocks With Bullish Analyst Reviews And Big Upside Potential

2020-06-27 11_57_21-Crop nurse with syringe on beige background · Free Stock PhotoClinical trial data or regulatory verdicts can send shares of biotech companies skyrocketing – or plummeting. The question then, as the author of today’s article observes, is “how are investors supposed to determine which biotech stocks are capable of outperforming the rest?” One approach is to track analyst sentiment – and the author highlights three biotech stocks that not only are analysts bullish on but which are trading for less than $5 a share and boast upside potential of over 100%. For more, CLICK HERE.

Read More

These 2 Small-Cap Biotech And Pharma Stocks Boast “Strong Buy” Ratings And Significant Upside Potential

2020-06-23 20_12_04-Set of pills with heap of paper money · Free Stock PhotoToday’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.

Read More

The Best Of Times To Bet On Biotech Penny Stocks?

2020-06-20 15_23_04-Coins Inside Jar · Free Stock Photo“Biotech penny stocks have always been a big focus for investors but this year has been one of the most active years for the sector,” observes the author of today’s article. And while the coronavirus outbreak has been a major reason for this increased activity, the author notes that “you also have companies hitting big milestones for other health indications.” With this being perhaps one of the best times to bet on biotech penny stocks, the author highlights four in particular to have a look at. For more, CLICK HERE.

Read More

Top Tech Trading Under $10

2020-06-13 00_10_18-green potted plant photo – Free Plant Image on UnsplashBased on the premise that tech is poised to continue to drive the market for years to come, today’s article highlights three cheap (trading under $10 a share) stocks from the broader technology space to consider due to their growth prospects regardless of renewed market volatility. For more on these three tech stocks, CLICK HERE.

Read More

Now That Its Shares Have Cooled Off A Bit, Is It Time To Buy This “Flaming Hot” Biotech Stock?

2020-06-10 22_21_15-shallow photography of wood burning photo – Free Fire Image on UnsplashShares of the small-cap biotech stock highlighted in today’s article have settled back down after surging more than 70% earlier this month in reaction to interim results for the company’s only drug candidate to reach the clinical trial phase. Does that make now a good time to buy? For more on this “flaming hot” biotech firm that could “become a maverick in developing a therapeutic candidate for [a] significant medical need”, CLICK HERE.

Read More

The Best Way To Play This – And Other – COVID-19 Biotech Stocks

2020-06-04 22_28_52-Crop chemist holding in hands molecule model · Free Stock PhotoThe biotech stock highlighted in today’s article is one of the many that has surged over the last few months due to its status as a potential COVID-19 play, with the company in question being the producer of a COVID-19 test. As with all the smaller biotechs that have been experiencing COVID-19-related surges lately, however, the question is whether that surge is sustainable or justified, and what the best way to play the stock (and its counterparts) may be. For more, CLICK HERE.

Read More

2 Of The Most Promising Stocks In The Young – But Rapidly Growing – Gene Editing Space

2020-05-16 22_17_46-WindowWhen it comes to the nascent – but rapidly growing – gene editing space, the author of today’s article notes that “sector players are rapidly making progress in combating rare or difficult to treat diseases that traditional chemical based drugs simply cannot accomplish.” With the market for gene editing therapies expected to grow by over 18% annually, he highlights two of the most promising gene editing stocks for biotech investors to consider. For more, CLICK HERE.

Read More

3 Potential “Game-Changer” Biotech Stocks With Triple-Digit Upside Potential

2020-05-08 20_58_20-Unrecognizable chemist taking liquid with pipette from test tube in modern labor“Veteran players of the stock picking game know that biotechs are capable of delivering a win at what feels like the drop of a hat,” notes the author of today’s article, who proceeds to highlight three biotech stocks, identified by investment firm Wedbush, with the potential to be game-changers. For these three Buy-rated biotech stocks with triple-digit upside potential, CLICK HERE.

Read More